RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth

Hyperactivated AKT/mTOR signaling is a hallmark of pancreatic neuroendocrine tumors (PNETs). Drugs targeting this pathway are used clinically, but tumor resistance invariably develops. A better understanding of factors regulating AKT/mTOR signaling and PNET pathogenesis is needed to improve current...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Invest
Main Authors: Umesalma, Shaikamjad, Kaemmer, Courtney A., Kohlmeyer, Jordan L., Letney, Blake, Schab, Angela M., Reilly, Jacqueline A., Sheehy, Ryan M., Hagen, Jussara, Tiwari, Nitija, Zhan, Fenghuang, Leidinger, Mariah R., O’Dorisio, Thomas M., Dillon, Joseph, Merrill, Ronald A., Meyerholz, David K., Perl, Abbey L., Brown, Bart J., Braun, Terry A., Scott, Aaron T., Ginader, Timothy, Taghiyev, Agshin F., Zamba, Gideon K., Howe, James R., Strack, Stefan, Bellizzi, Andrew M., Narla, Goutham, Darbro, Benjamin W., Quelle, Frederick W., Quelle, Dawn E.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6436899/
https://ncbi.nlm.nih.gov/pubmed/30721156
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI123049
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados